Literature DB >> 2883237

Heterogeneity in response to interleukin 2 and interleukin 2-producing ability of adult T cell leukemic cells.

N Arima, Y Daitoku, Y Yamamoto, K Fujimoto, S Ohgaki, K Kojima, J Fukumori, K Matsushita, H Tanaka, K Onoue.   

Abstract

To examine the possibility of heterogeneous mechanisms in the proliferation of adult T cell leukemia (ATL) cells, leukemic cells from 13 patients, nine acute-type and four chronic-type ATL, were examined for the production of interleukin 2 (IL 2) with or without mitogenic stimulation and their response to recombinant IL 2 when exogeneously added. The leukemic cells were classified into four groups, as follows. Group 1 (two patients): Cells of this group produced IL 2 messenger RNA, secreted IL 2, and proliferated when cultured in mitogen-free medium. The spontaneous proliferation of the cells in mitogen-free medium was inhibited by anti-Tac/IL 2 receptor and anti-IL 2 monoclonal antibodies. Moreover, the thymidine incorporation by the cells was enhanced in response to exogeneously added recombinant IL 2 and IL 2 produced by themselves. These results indicate that the ATL cells of this group proliferate with autostimulation by IL 2. Group 2 (seven patients): Cells of this group did not secrete IL 2 when cultured in mitogen-free medium, but the cells showed response to exogeneously added recombinant IL 2 and proliferated in culture. These results indicate that the ATL cells of this group proliferate by a paracrine mechanism. Group 3 (one patient): Cells of this group secreted IL 2 in mitogen-free medium. However, the spontaneous proliferation of these cells in vitro was very low, and the response to recombinant IL 2 was also very low. Group 4 (three patients): Cells of this group did not secrete IL 2 in mitogen-free medium. Spontaneous proliferation and the response to recombinant IL 2 were also very low. The clinical feature of all patients of Groups 1 and 2 was acute-type, and that of Groups 3 and 4 was chronic-type. Thus, we conclude that heterogeneous mechanisms exist in the proliferation of leukemic cells, and that growth rate in mitogen-free medium and response to IL 2 of the cells may have a significant relationship to the clinical feature, acute- or chronic-type.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883237

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.

Authors:  Jing Chen; Mike Petrus; Bonita R Bryant; Vinh Phuc Nguyen; Carolyn K Goldman; Richard Bamford; John C Morris; John E Janik; Thomas A Waldmann
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

2.  Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro.

Authors:  A Tanaka; C Takahashi; S Yamaoka; T Nosaka; M Maki; M Hatanaka
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  Spontaneous production of interleukin 6 by adult T-cell leukaemia cells.

Authors:  T Sawada; H Tsuda; K Takatsuki
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

4.  Expression of cytokine mRNA in leukemic cells from adult T cell leukemia patients.

Authors:  T Kodaka; T Uchiyama; H Umadome; H Uchino
Journal:  Jpn J Cancer Res       Date:  1989-06

5.  Transient induction of IL-2 receptor in cultured T cell lines by HTLV-1 LTR-linked tax-1 gene.

Authors:  T Doi; M Hatakeyama; S Itoh; T Taniguchi
Journal:  EMBO J       Date:  1989-07       Impact factor: 11.598

6.  Enhancing effect of interleukin-2 on production of parathyroid hormone-related protein by adult T-cell leukemia cells.

Authors:  N Mori; K Ohsumi; S Murakami; A Wake; F Shirakawa; I Morimoto; S Oda; S Eto
Journal:  Jpn J Cancer Res       Date:  1993-04

Review 7.  Dysregulation of growth factor-receptor system in cellular transformation.

Authors:  M Hatakeyama; T Taniguchi
Journal:  Jpn J Cancer Res       Date:  1988-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.